For more than 15 years, Tim Shannon has been an entrepreneur, researcher, professor, and a practicing physician in pulmonary and critical care medicine. A Canaan investor since 2009, we rely on Tim's operating experience to help companies grow from university technologies to funded companies. Most recently, Tim was startup CEO of Arvinas. He serves on the boards of CytomX Therapeutics (CTMX), NextCure, Spyryx Biosciences, Vivace Therapeutics, and is a director at Celldex Therapeutics, which acquired CuraGen in October 2009.
Prior to Canaan, Tim was president and chief executive officer of CuraGen, a biopharmaceutical company focused on oncology, after serving as executive vice president of R&D and chief medical officer. He also held positions of increasing responsibility for Bayer's Pharmaceutical Business Group including senior vice president of global medical development.
Tim was assistant professor of the pulmonary and critical care division at Yale University School of Medicine and an attending physician in pulmonary and critical care medicine at the West Haven V.A. Medical Center. Tim received his post graduate medical training at the Beth Israel Hospital of Harvard Medical School and at Boston University, earned his medical degree from the University of Connecticut, and has a B.A. in chemistry from Amherst College.
"Enjoy when you can, and endure when you must."- Johann Wolfgang von Goethe
Generating new ideas while running long distances, and getting outside with my family - anywhere outside. I also enjoy quiet time at 5am (when else can you find it?) and reading history, especially history I know nothing about... which is most of it.